查詢結果分析
來源資料
相關文獻
- Percutaneous Ethanol Injection and Radiofrequency Ablation for Treatment of Hepatocellular Carcinoma Less Than 2 CM
- 早期肝癌局部療法:射頻燒灼與酒精注射之比較
- Percutaneous Radiofrequency Ablation for Hepatocellular Carcinoma
- Use of Color Ultrasound in Percutaneous Intravascular Ethanol Injection into the Supplying Vessel of a Hepatocellular Carcinoma: Report of a Case
- Sclerosing Hepatocellular Carcinoma: Imaging and Pathological Features
- Intraperitoneal Distant Implantation after Repeated Radiofrequency Ablation for Hepatocellular Carcinoma: Report of Two Cases
- 射頻燒灼治療於消融肝腫瘤的應用
- 肝癌治療的現況
- Percutaneous Radio-Frequency Ablation of Liver Malignancies
- 射頻燒灼術在肝癌的治療
頁籤選單縮合
題名 | Percutaneous Ethanol Injection and Radiofrequency Ablation for Treatment of Hepatocellular Carcinoma Less Than 2 CM=酒精注射及無線射頻燒灼對小於2公分之肝癌的治療 |
---|---|
作者 | 蔡毓洲; 李英俊; 羅海韻; 陳錫榮; 孫盟舜; 蔡青陽; 曾建森; 陳寶輝; Tsai, Yu-jou; Li, Ying-chun; Lo, Hoi-wan; Chen, His-jung; Sun, Meng-shun; Tsai, Ching-yang; Tseng, Chien-sen; Chen, Pao-huei; |
期刊 | 臺灣消化醫學雜誌 |
出版日期 | 20110900 |
卷期 | 28:3 2011.09[民100.09] |
頁次 | 頁271-280 |
分類號 | 416.246 |
語文 | eng |
關鍵詞 | 肝癌; 射頻燒灼; 酒精注射; Hepatocellular carcinoma; Radiofrequency ablation; Ethanol injection; |
中文摘要 | 研究動機:目前有關射頻燒灼對於早期肝癌的文獻報告多以腫瘤大小3公分爲分界,然而隨著高危險群病人接受篩檢的普及與影像學的進步,肝癌小於2公分的病例逐漸增加,這類病患是否也需要使用射頻燒灼呢?其療效是否優於酒精注射?兩者之成本效益與風險評估如何?目前文獻報告並無法提供很完整的答案。本研究利用統計分析來評估兩者差異,以供面對抉擇時,醫療提供者、病患本人或家屬、甚或保險單位可以參考運用。材料方法:我們從阮綜合醫院之癌登資料內,收集自2002年1月1日至2009年6月30日止的肝癌病人,篩選出罹患單顆小於2公分之極小肝癌,且初始治療爲接受射頻燒灼或酒精注射者爲納入條件,共有41位病患符合篩選條件:酒精注射組有22位:男13位,女9位,平均年齡63.7歲;射頻燒灼組有19位:男13位,女6位,平均年齡62.6歲。以這兩組病人,進行回溯性的病例對照研究,追蹤至2010年6月30日止。先從兩組的基本資料,包括性別、年齡、實驗室檢查資料、肝癌復發之危險因子、預後影響因子等,進行比對,以確認兩組病人是否有統計學上之差異,再從住院天數、醫療費用、併發症發生率、局部及他處復發率、無復發存活率及總體存活率等方面,評估比對兩組之成本效益與風險。結果:兩組的基本背景資料、復發危險因子及預後因子等方面並無統計上的顯著差異,但在醫療費用上有統計上的顯著差異(P<0.001):完整治療一位罹患極小肝癌患者,用酒精注射平均花費新台幣14,269元;用射頻燒灼平均花費新台幣37,278元,兩組差爲新台幣23,009元。而兩組在住院天數、併發症的發生率、治療後的局部及他處復發率、無復發存活率與總體存活率方面,則無統計上的差異。結論:雖說本研究的樣本數較小,對於小於2公分之肝癌而言,本研究之結論爲,當其基本的背景資料、復發危險因子及預後因子等方面並無統計上的顯著差異時,射頻燒灼在醫療資源的花費上明顯高於酒精注射,而住院天數、併發症的發生率、治療後的局部及他處復發率、無復發存活率與總體存活率方面,則與酒精注射無統計上的差異,顯示酒精注射合乎成本效益。 |
英文摘要 | Background and Aims: Detection rates of hepatocellular carcinomas (HCC) smaller than 2 cm in diameter are increasing because high risk patients are receiving more regular screenings. The aim of this study was to determine whether radiofrequency ablation (RFA) or percutaneous ethanol injection (PEI) is better for a patient with very small HCC.Materials and Methods: We retrospectively obtained data on patients with very small HCC from the database of Yuan's General Hospital. Of the 770 patients with HCC who were treated between January 1, 2002, and June 30, 2009, those who received PEI (n=22) or RFA (n=19) as the first-line nonsurgical treatment became subjects for further analysis. We compared the patients' baseline characteristics as well as the hospital stay, mean cost, complication rate, local tumor progression and new recurrent rate, recurrence free survival, and overall survival rate by group until the end of follow-up on June 30, 2010.Results: Analysis of baseline characteristics revealed no statistically significant differences between the two groups. Nevertheless, the RFA group had a higher mean cost (37,278 versus 14,269 new Taiwan dollars, P<0.001). Hospital stay, complication rate, local tumor progression and new recurrent rate, recurrence free survival, and overall survival between these two groups were not significantly different.Conclusions: Based on the current result derived from small sample size, for patients with very small single HCC (< 2 cm diameter), RFA resulted in significantly higher costs without significant differences in hospital stay, complication rate, recurrence free survival, or overall survival compared to PEI. |
本系統之摘要資訊系依該期刊論文摘要之資訊為主。